Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 438, 967-974 (15 December 2005) | doi:10.1038/nature04483; Published online 14 December 2005
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Electrophysiologist
- TCG Lifesciences Ltd
- Kolkata India
Tenure-Stream Position in Oral Microbiology
- University of Toronto
- Toronto, ON Canada
Review Article Angiogenesis as a therapeutic target
Napoleone Ferrara1 & Robert S. Kerbel2
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Targeted therapies Goldie?Coldman and bevacizumab beyond disease progressionNature Reviews Clinical Oncology News and Views (01 Jun 2009)
